Company Overview and News
After nearly collapsing during the financial crisis in 2008, American International Group (AIG - Free Report) was once of the most high-profile beneficiaries of U.S. government intervention in the Troubled Asset Relief Program, commonly referred to as TARP.
Chicago, IL – May 22, 2018 – Zacks Equity Research highlights Akamai Technologies (AKAM - Free Report) as the Bull of the Day and American International Group (AIG - Free Report) as the Bear of the Day. In addition, Zacks Equity Research provides analysis on Walmart (WMT - Free Report) , Amazon (AMZN - Free Report) and Kroger (KR - Free Report) .
This article is part of a series that provides an ongoing analysis of the changes made to Carl Icahn's 13F portfolio on a quarterly basis. It is based on Icahn's regulatory 13F Form filed on 05/15/2018. Please visit our Tracking Carl Icahn's Portfolio series to get an idea of his investment philosophy and our previous update for the fund's moves during Q4 2017.
Stocks have seen a recovery for much of the week, but major equity indexes were all marginally lower on Thursday morning. The trend of endless buying the dips has not worked well lately, and many investors are wondering whether the best has been seen for 2018. Now all investors have to consider how they want their investments positioned for the longer term.
The Finance sector, which has been in the spotlight since the U.S. Presidential elections in November 2016, reported impressive first-quarter 2018 results. Per the latest Earnings Preview, the S&P 500 finance stocks recorded 24.7% year-over-year earnings improvement. This was mainly driven by favorable macroeconomic factors, higher interest rates, decent loan and deposit growth, and lower tax rates.
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
LUXEMBOURG: Luxembourg’s citizens can quickly impress with their language skills, switching with ease between their local tongue and German, French and English.
This copy is for your personal, non-commercial use only. To order presentation-ready copies for distribution to your colleagues, clients or customers visit http://www.djreprints.com.
Menlo Therapeutics Inc. (NASDAQ:MNLO) has 10 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 2,342,011 shares. Largest shareholders include Venbio Partners L.p., BlackRock Inc., Franklin Resources Inc, JP Morgan Chase & Co, Northern Trust Corp, Schwab Charles Investment Management Inc, American International Group Inc, New York State Common Retirement Fund, Strs Ohio, and Wells Fargo & Company/mn.
NEW YORK (Reuters) - American International Group Inc (AIG.N) faces an uphill climb to convince shareholders to approve a $43.1 million pay package for Chief Executive Officer Brian Duperreault during the company’s annual meeting on Wednesday.
BRUSSELS, May 8 (Reuters) - The following are mergers under review by the European Commission and a brief guide to the EU merger process:
REUTERS: Billionaire investor Carl Icahn has sold his stake in American International Group Inc , ending a more than two-year association with one of the largest U.S. property and casualty insurers, according to a person familiar with the matter.
BRUSSELS, May 7 (Reuters) - The following are mergers under review by the European Commission and a brief guide to the EU merger process:
The largest US investment banks (XLF) saw FICC (fixed income, currencies and commodities) trading revenues of $14.45 billion in 1Q18—76% higher compared to 4Q17. Banks’ FICC trading revenues increased due to increased volatility across capital markets that boosted the demand for debt and currency trading services. JPMorgan Chase (JPM) took the top spot from Citigroup (C). Goldman Sachs (GS) saw its FICC trading revenues rise 23% year-over-year due to its weak performance last year.
BROWSER UPDATE To gain access to the full experience, please upgrade your browser: Chrome | Safari | Firefox | Internet Explorer
2018-05-21 - Asif
Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...
2018-05-21 - Asif
Business Agenus is a clinical-stage immuno-oncology (“I-O”) company dedicated to becoming a leader in the discovery and development of innovative combination therapies and committed to bringing effective medicines to patients with cancer. The company's business is designed to drive success in I-O through speed, innovation, and effective combination therapies. Agenus has assembled fully integrated capabilities from novel target discovery, antibody generation, cell line development, and good manufacturing practice (“GMP”) manufacturing together with a comprehensive portfolio consisting of antibody-based therapeutics, adjuvants and cancer vaccine platforms. The company leverage its immune biology platforms to identify effective combination therapies for development and have developed productive partnerships to advance its innovation. The company believe the next generation of cancer treatment will build on clinically validated antibodies targeting CTLA-4 and PD-1 combined wi...
2018-05-21 - Asif
Business The company started Square in February 2009 to enable businesses (sellers) to accept card payments, an important capability that was previously inaccessible to many businesses. However, sellers also need innovative solutions to thrive, and Square has since expanded to provide additional products and services to give these businesses access to the same tools as large businesses. This approach aligns with its purpose of economic empowerment, as everything the company do should give sellers accessible, affordable tools to grow their businesses and participate in the economy. Square is a cohesive commerce ecosystem that helps its sellers start, run, and grow their businesses. The company combine sophisticated software with affordable hardware to enable sellers to turn mobile and computing devices into powerful payment and point-of-sale solutions. Square has high seller acceptance rates and fast onboarding, while maintaining low risk and fraud losses as a result of its a...
as of ET